Search Results
Aug 27, 2025, 07:15 ET ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025
treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Aug 27, 2025, 06:08 ET Innovent Announces 2025 Interim Results and Business Updates
Oncology: IBI3009 (DLL3 ADC), IBI3001 (EGFR/B7H3 ADC), IBI3003 (GPRC5D/BCMA/CD3), IBI3005 (EGFR/HER3 ADC), IBI3014 (PD-L1/TROP2 ADC), IBI3020 (CEACAM5 dual-payload ADC), etcCVM: IBI3016 (AGT siRNA), IBI3032 (oral GLP-1),
More news about: Innovent Biologics
Aug 27, 2025, 02:17 ET Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum
and seasonal allergic rhinitis (SAR), with Phase III trials ongoing in pediatric AD and prurigo nodularis.CMG901/AZD0901 (Claudin 18.2 ADC): In 2023, AstraZeneca AB (AZ) was granted an exclusive global license for research, development, registration, manufacturing, and commercialization
More news about: Keymed
Aug 27, 2025, 02:02 ET Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum
and seasonal allergic rhinitis (SAR), with Phase III trials ongoing in pediatric AD and prurigo nodularis.CMG901/AZD0901 (Claudin 18.2 ADC): In 2023, AstraZeneca AB (AZ) was granted an exclusive global license for research, development, registration, manufacturing, and commercialization
More news about: Keymed
Aug 26, 2025, 12:52 ET Akeso's 2025 Interim Results: Commercial Sales Reach New All-Time Highs
including progression-free survival (PFS) and OS. At the same time, our lead bispecific-ADC, AK146D1, and a next-generation ADC, AK138D1, have entered global early-stage clinical trials. Additional bispecific-ADC and ADC candidates are currently being developed. Both ivonescimab and cadonilimab
More news about: Akeso, Inc.
Aug 26, 2025, 09:00 ET iNtRON Bio, files Two Patent Applications for IMPA™ Platform-Based Gene Editing Technology
are enhancing the completeness of the technology, which will serve as the foundation for iNtRON Bio to develop various new drug candidates, including ADC drugs, anticancer agents, and vaccines." Contact USYOON, Kyung Won (Kevin) / CEO, Vice President
More news about: iNtRON Biotechnology, Inc.
Aug 26, 2025, 08:30 ET ADCs in Oncology Trials: Practical Strategies for Clinical Development Success, Upcoming Webinar Hosted by Xtalks
conjugate (ADC) clinical development. Attendees will learn about the rapid evolution of ADCs in oncology and how they have revolutionized the cancer treatment landscape. The featured speakers will discuss how to navigate an increasingly competitive landscape and ensure operational excellence in ADC trial
More news about: Xtalks
Aug 26, 2025, 08:30 ET Advancing ADC Design Through Site-Specific Conjugation and Stable Linkers, Upcoming Webinar Hosted by Xtalks
next-generation antibody-drug conjugates (ADCs) and emerging strategies in ADC conjugation and linker design. Attendees will learn how site-specific conjugation and optimized linker strategies can improve the drug-antibody ratio (DAR) and enhance ADC efficacy while reducing toxicity. The featured speaker will discuss
More news about: Xtalks
Aug 25, 2025, 09:14 ET Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach
investigational novel endocrine therapy, the company's novel epitope anti-HER2 mAb HLX22, the next-gen innovative HER2 ADC HLX87, the KAT6A/B inhibitor HLX97 with BIC potential, and the LIV-1 ADC HLX41 are accelerating their research progress. In more disease fields, HLX04-O, a recombinant anti-VEGF
More news about: Henlius
Aug 25, 2025, 08:58 ET 復宏漢霖2025H1業績：高質量穩健增長，海外產品利潤激增超200%，加速創新管線全球兌現
®形成序貫治療方案，以降低早期患者復發風險；同時，公司自研的帕妥珠單抗生物類似藥HLX11已獲中美歐監管機構受理上市申請，有望於下半年在美國獲得批准。聚焦這一疾病領域，公司持續打造更完善的創新產品矩陣，新型內分泌療法拉索昔芬片HLX78、新表位抗HER2單抗HLX22、HER2 ADC HLX87、早期潛力分子KAT6A/B靶向小分子抑制劑HLX97及LIV-1靶向ADC HLX41正在加速布局。 在更多疾病領域，公司與億勝生物合作開發的重組抗VEGF單抗HLX04-O治療濕性年齡相關性黃斑變性(wAMD)已於2025年8月在中國獲上市注冊申請（NDA）受理，為公司首款申報上市的眼科產品。地舒單抗生物類似藥HLX14用於治療骨質疏松症等的上市注冊申請已獲得美國、歐盟和加拿大受理，有望於2025下半年獲得批准。
More news about: 復宏漢霖
Aug 25, 2025, 08:30 ET ADC Development: Early On- and Off-Target Testing to Fail Fast, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn why antibody-drug conjugate (ADC) programs benefit from a "fail faster" approach to reduce late-stage attrition and accelerate development. Attendees will gain insight into how early in vitro testing helps identify both on-target efficacy and off-target toxicity
More news about: Xtalks
Aug 25, 2025, 06:19 ET Acceleration in Clinical Development! Leads Biolabs' LBL-034 Dosed First Patient in Phase Ⅱ Trial
proprietary technology platforms, including LeadsBody™ platform (a CD3 T-cell engager platform), X-body™ platform (a 4-1BB engager platform) , Linker-payload (ADC platform), which serve as the cornerstone for our continued innovation and have been validated by the clinical outcomes of our bispecific antibody portfolios.
More news about: Leads Biolabs
Aug 25, 2025, 03:00 ET Antengene Announces 2025 Interim Results with Encouraging Clinical Data and Progress in TCE Platform
ATG-022 (CLDN18.2 ADC) has shown promising results in the ongoing Phase I/II CLINCH study, demonstrating robust efficacy and a favorable safety profile in gastric/GEJ
More news about: Antengene Corporation Limited
Aug 24, 2025, 20:00 ET Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer
innovative therapies worldwide. In addition to IBI363, Innovent is advancing a broader pipeline for global development, including next-generation ADC programs such as bispecific and dual-payload ADCs. We believe our robust pipeline and ongoing R&D efforts will continue to expand our impact in oncology
More news about: Innovent Biologics
Aug 22, 2025, 06:12 ET Weekly Recap: 14 Health Press Releases You Need to See
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer The
More news about: PR Newswire
Aug 22, 2025, 06:11 ET Antengene Announces 2025 Interim Financial Results Highlighting Encouraging Data from Mid/Late-Stage Clinical Programs and Its Innovative TCE Technology Platform
medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA
More news about: Antengene Corporation Limited
Aug 21, 2025, 17:46 ET Uveal Melanoma Market Analysis Across the 7MM: Key Insights and Outlook Through 2034 | DelveInsight
first-in-class PKC inhibitor for adults with primary uveal melanoma where enucleation is recommended. DYP688 is an antibody-drug conjugate (ADC), consisting of an antibody linked to a cytotoxic agent. The antibody targets PMEL17, a protein found on GNAQ/11-mutated melanoma cells. Upon
More news about: DelveInsight Business Research, LLP
Aug 19, 2025, 20:00 ET 晶泰科技與韓國東亞公司簽署合作，共同研發免疫與炎症領域新藥
關於東亞公司 東亞公司 (Dong-A ST Co., Ltd.,170900.KO) 成立於1932年，是韓國領先的醫藥企業，致力於處方藥、生物類似藥、醫療器械及診斷試劑的研發、生產和商業化。其核心產品包括Stillen（胃炎用藥）、Zydena（勃起功能障礙用藥）、Motilitone（功能性消化不良用藥）和Imuldosa（烏司奴單抗生物類似藥）。依托強大的研發實力和創新歷史，東亞公司正持續擴展其在免疫、炎症、神經疾病、代謝性疾病和腫瘤學領域的研發管線，並積極布局生物藥、ADC、TPD及基因療法等新型治療模式。 關於晶泰科技晶泰科技（「XtalPi
More news about: 晶泰科技
Aug 19, 2025, 20:00 ET XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies
expand its R&D scope beyond small molecule therapeutics into areas such as targeted protein degradation (TPD), biologics, antibody-drug conjugates (ADC), and gene therapies. John Wang, Senior Vice President of Drug Discovery at XtalPi, stated: "The combination of
More news about: XtalPi Inc.
Aug 19, 2025, 10:00 ET Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA
/PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the U.S. Food and Drug Administration (FDA). The clearance enables
More news about: Mabwell
Aug 19, 2025, 08:45 ET BittWare Launches Early Access Program for 3U VPX Cards Featuring Next-Generation AMD Ryzen Embedded Processors and Versal Adaptive SoCs for Aerospace and Defense Systems
demonstrate RFX Surfer, a graphical user interface for the RFX and WaveBox™ family of direct RF solutions. This tool gives users easy access to configure ADC/DAC channels and adjust the suite of analog and digital controls—all running on a standalone system. About Molex: Molex is a global
More news about: Molex Incorporated
Aug 19, 2025, 07:48 ET Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC
are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Aug 19, 2025, 06:39 ET Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma
first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that its in-house discovered CLDN18.2 ADC, ATG-022,was granted a Breakthrough Therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA)
More news about: Antengene Corporation Limited
Aug 19, 2025, 00:42 ET Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma
first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that its in-house discovered CLDN18.2 ADC, ATG-022,was granted a Breakthrough Therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA)
More news about: Antengene Corporation Limited
Aug 18, 2025, 09:05 ET WuXi XDC Continues to Deliver Robust Business Growth and Financial Results in 1H 2025, Strengthening Global CRDMO Leadership Position in Bioconjugates Industry
number of customers and projects, driven by continued active development of the global ADC and broader bioconjugates market, (ii) the increasing market share through the Group's established position as a leading ADC CRDMO service provider in that market, and (iii) the steady advancement of the Group's
More news about: WuXi XDC